Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

In Vitro Effects of Ciprofloxacin and Roxithromycin on Apoptosis of Jurkat T Lymphocytes

Yong-Taek Jun, Hee-Jung Kim, Min-Jin Song, Ji-Hyang Lim, Dong-Gun Lee, Kyung-Ja Han, Su-Mi Choi, Jin-Hong Yoo, Wan-Shik Shin, Jung-Hyun Choi
Yong-Taek Jun
1Division of Infectious Diseases, Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hee-Jung Kim
2Clinical Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min-Jin Song
2Clinical Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ji-Hyang Lim
3Department of Clinical Pathology, College of Medicine, Catholic University of Korea, Seoul, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dong-Gun Lee
1Division of Infectious Diseases, Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyung-Ja Han
3Department of Clinical Pathology, College of Medicine, Catholic University of Korea, Seoul, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Su-Mi Choi
1Division of Infectious Diseases, Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin-Hong Yoo
1Division of Infectious Diseases, Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wan-Shik Shin
1Division of Infectious Diseases, Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jung-Hyun Choi
1Division of Infectious Diseases, Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cmcjh@catholic.ac.kr
DOI: 10.1128/AAC.47.3.1161-1164.2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Ciprofloxacin (CPFX) and roxithromycin (RXM) induced apoptosis of activated Jurkat T cells in vitro. CPFX showed concentration-dependent acceleration of apoptosis of activated Jurkat T cells by enhancing the expression of FasL and activities of caspase-3 and -8. RXM accelerated cell death, enhanced expression of FasL and caspase-3 but not caspase-8, and did not show the concentration dependency.

Apoptosis, or programmed cell death, is a regulated physiological process essential for embryogenesis and for maintaining cellular homeostasis. Apoptosis is a constitutive process, but it can be induced or inhibited by various stimuli. Recently, the pathogenesis of numerous diseases, such as cancerous diseases, autoimmune diseases, and inflammatory diseases, have been explained by the alteration of normal regulation of apoptosis (1, 26, 32, 34).

Antibiotics are widely used as bacteriostatic or bactericidal drugs in the therapy of bacterial infections. Besides the respective interactions between antibiotics and bacteria and between the immune system and bacteria, antibiotics also directly interact with the immune system (15, 17, 18). Immunomodulatory effects of antibiotics include alteration of phagocytosis, chemotaxis, endotoxin release, cytokine production, and tumoricidal effects of certain cells. Moreover, some antibiotic agents can affect the life span of cells through inducing or inhibiting apoptosis (4, 6, 18). Among numerous immunomodulatory antibiotics, the immunomodulatory effects of quinolones and macrolides are the major part of the reports in this field (12, 13, 16, 21, 24, 27, 28, 33).

In this study, we wanted to evaluate the effects of ciprofloxacin (CPFX) and roxithromycin (RXM), widely used quinolone and macrolide, on the apoptosis of activated Jurkat T cells. If CPFX or RXM can alter the apoptotic patterns of Jurkat T cells, the immune responses elicited by T cells could be modified and the immunologic effects of CPFX and RXM in clinical practice might be inferred. We analyzed the effect of CPFX or RXM on the viability of activated Jurkat T cells and altered expression of well-known regulators of apoptosis, such as Fas, FasL, Bcl-2, Bax, caspase-3, and caspase-8.

An acute T-cell leukemia cell line, Jurkat (clone E6-1, ATCC TIB-152), was purchased from American Type Culture Collection (Manassas, Va.). Jurkat T cells were maintained in RPMI-1640 (Gibco, Gaithersburg, Md.) containing 10% fetal calf serum (Gibco), 20 mM HEPES, and 1% antibiotic-antimycotic solution (100 U of penicillin, 100 μg of streptomycin, 0.25 μg of amphotericin B; Gibco). The cells were pretreated with various concentrations of CPFX (1, 2.5, 5, and 10 μg/ml; Dong-A Pharm. Co., Ltd., Seoul, Korea) or RXM (1, 10, 20, and 50 μg/ml; Sigma Chemical Co., St. Louis, Mo.) for 2 h at 37°C in 24-well plates (Nunc, Roskilde, Denmark). Cells were then incubated with anti-CD3 antibody for activation (clone HIT3a; 10 ng/ml; PharMingen, San Diego, Calif.).

Viability of Jurkat T cells after treatment was analyzed by MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) assay (R&D Systems, Inc., Minneapolis, Minn.). A total of 6 × 105 Jurkat T cells per well were incubated at 37°C with anti-CD3 antibody, with or without CPFX or RXM, for the indicated time periods. The absorbance was read at 550 nm with a spectrophotometer, and the percentages of viable cells were calculated.

DNA fragmentation was assessed by an enzyme-linked immunosorbent assay (ELISA) kit (Boehringer Mannheim, Mannheim, Germany). In brief, 3 × 105 Jurkat T cells were labeled with 1 mM 5-bromo-2′-deoxyuridine (BrdU) for 6 h. Anti-CD3 antibody with or without CPFX or RXM was added and incubated for 12 to 72 h. DNA fragmentations were then measured according to the manufacturer's protocols.

Cell surface expression of Fas was assayed by direct immunofluorescence flow cytometry with a saturating concentration of fluorescein isothiocyanate (FITC)-conjugated mouse anti-human APO-1/Fas monoclonal antibody (clone DX2; 10 μl/106 cells; Dako, Glostrup, Denmark) after 18 h of treatment with anti-CD3 antibody with or without CPFX or RXM. Negative control cells were stained with a saturating concentration of irrelevant mouse anti-human APO-1/Fas monoclonal antibody.

Cell surface expression of FasL was assayed by indirect immunofluorescence flow cytometry by using anti-human FasL antibody for primary staining and FITC-conjugated, affinity-purified F(ab′)2 goat anti-human immunoglobulin G (FITC-conjugated anti-mouse immunoglobulin G1; Dako) for secondary staining. Negative control staining was performed by omitting FasL antibody in the primary step. The plates were kept at 4°C until the flow cytometry assay was performed with FACScan and LYSIS II software (Becton Dickinson, San Jose, Calif.). Mean fluorescence intensity was calculated after subtracting the mean fluorescence intensity of the negative control.

Bcl-2 and Bax expressions were measured by a commercial ELISA method (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.). Proteins were extracted from 5 × 105 Jurkat T cells after 18 h of culture with anti-CD3 antibody with or without CPFX or RXM. Concentrations of proteins were measured according to the manufacturer's instructions.

We used caspase-3 and caspase-8 colorimetric assay kits (R&D Systems) for analysis. In brief, 2 × 106 cells were collected, and the cellular pellet was lysed by cell lysis buffer after 18 h of treatment with anti-CD3 antibody with or without CPFX or RXM. Caspase-3 and caspase-8 were measured by colorimetric assay according to the manufacturer's instructions by using a spectrophotometer at 405 nm.

Results are shown as means ± standard errors of the means (SEM) for triplicate or quadruplicate experiments. Statistical analysis was conducted by using analysis of variance with Tukey's method. A P value of <0.05 was judged to be statistically significant.

Anti-CD3-activated Jurkat T cells (control) were less viable than untreated cells with time. Addition of CPFX or RXM accelerated the death of activated Jurkat T cells in a concentration-dependent manner, especially CPFX-treated cells (Fig. 1).

The DNA fragmentation of Jurkat T cells treated with CPFX was greater than that of untreated and control cells. It caused more fragmentation at higher concentrations. But addition of RXM significantly increased fragmentation only at 72 h and did not show concentration dependency (Fig. 2).

The percentage of Fas-expressing cells was increased in control cells (87.5% ± 3.2%) compared to that in untreated cells (80.5% ± 2.4%). But the addition of CPFX or RXM did not result in any difference in Fas expression compared to that of control cells. The percentage of FasL-expressing cells was also increased in control cells compared to that in untreated cells (21.3% ± 2.1% versus 10.6% ± 3.2%). Addition of CPFX increased FasL-expressing cells to 29.5% ± 1.6% (2.5 μg/ml, P < 0.05) and 34.9% ± 1.1% (10 μg/ml, P < 0.05). Addition of RXM also increased FasL-expressing cells to 26.2% ± 1.8% (10 μg/ml, P < 0.05) and 25.9% ± 1.2% (50 μg/ml, P < 0.05). The expression of FasL was more remarkably increased in the CPFX-treated cells than in RXM-treated cells.

The Bcl-2/Bax ratio decreased with time in untreated Jurkat T cells. There is no significant alteration of the Bcl-2/Bax ratio in control cells or in CPFX- or RXM-treated cells compared to that in untreated cells (data not shown).

Control cells showed enhanced caspase-8 (optical density at 405 nm, 0.54 ± 0.10 versus 0.31 ± 0.09) and caspase-3 (0.86 ± 0.18 versus 0.10 ± 0.06) activities compared to those of untreated cells. Addition of CPFX increased caspase-8 activity at the concentrations of 2.5 μg/ml (0.72 ± 0.11, P < 0.05) and 10 μg/ml (0.83 ± 0.03, P < 0.05), and caspase-3 activity was also increased at the concentrations of 2.5 μg/ml (1.48 ± 0.09, P < 0.05) and 10 μg/ml (1.66 ± 0.12, P < 0.05). Addition of higher concentrations of CPFX tended to induce more caspases than lower concentrations, but there was no statistical difference between lower and higher concentrations (P > 0.05). Addition of RXM significantly increased the activity of only caspase-3 (1.39 ± 0.16, P < 0.05) compared to that of control cells at the concentration of 10 μg/ml, and there were no significant differences between lower and higher concentrations.

Recently, many reports about immunologic modifications, such as alteration of cellular proliferation and cytokines production from various cells, manifested by quinolones (CPFX, trovafloxacin, grepafloxacin) and macrolides (erythromycin, RXM, clarithromycin) have appeared (14, 22, 25, 29). Among immunomodulatory effects exerted by antimicrobials, we wanted to evaluate the effect of CPFX or RXM on apoptosis. In 1995, Aoshiba et al. reported erythromycin-induced apoptosis of human neutrophils, and they concluded that an increase of intracellular cyclic AMP might be the cause of this accelerated apoptosis (2). In 1999, Liu et al. reported doxycycline-induced apoptosis of Jurkat T cells (20). We wanted to analyze the effect of CPFX and RXM on the apoptosis of Jurkat T cells to compare our results with past published data and to find involved pathways of apoptotic processes. We used anti-CD3 antibody to activate Jurkat T cells. Anti-CD3 antibody is known as an activator and inducer of Fas/FasL-mediated apoptosis of T cells (3-5, 10, 20). We used four concentrations of each drug, three of which could be obtained in human blood and one that was beyond the range. The peak serum concentration of CPFX is 0.83 to ∼7.6 μg/ml, and that of RXM is 6 to ∼12 μg/ml according to the dose and route of administration and host factors (6, 12, 16). Addition of CPFX or RXM resulted in faster death than was seen with untreated or control cells, and the pattern of death showed concentration dependency in cells treated with CPFX (Fig. 1).

We chose two concentrations, one concentration within the range of serum peak level and one at maximal concentration, to maximize the difference in the following experiments. According to the cellular DNA fragmentation ELISA, apoptotic cell death of anti-CD3-activated Jurkat T cells was enhanced by addition of CPFX and increased at higher concentrations. But RXM enhanced apoptosis significantly only at 72 h after stimulation compared to that of control cells. To evaluate the underlying mechanisms of apoptosis, we investigated the expression of some well-known regulators of apoptosis. Fas and FasL, transmembrane receptors on the cell surface, are death regulators that belong to the tumor necrosis factor/nerve growth factor receptor family. Binding of FasL to Fas results in recruitment of a Fas-associated death domain. This complex activates caspases and initiates apoptosis (19, 23, 30, 34). In this study, CPFX and RXM up-regulated expression of FasL in the anti-CD3-activated Jurkat T cells, but up-regulation was more apparent in CPFX-treated Jurkat T cells. These results partially coincided with those of a study of apoptosis in doxycycline-treated Jurkat T cells which revealed more enhanced expression of FasL than Fas by addition of doxycycline (20).

Bcl-2 and Bax, other regulators of apoptosis, belong to the same family but have opposite actions: Bcl-2 inhibits apoptosis, but Bax accelerates apoptosis. In general, Bcl-2 binds to Bax, and the ratio of Bcl-2/Bax determines the fate of the cell (7, 8, 34). We evaluated the change of the Bcl-2/Bax ratio in the CPFX- or RXM-treated Jurkat T cells. Although we expected the additional synergy to accelerate apoptosis by alteration of Bcl-2 and Bax expression, the Bcl-2/Bax ratios were not different between antibiotic-treated and control cells. Therefore, the acceleration of death in CPFX- or RXM-treated Jurkat T cells might not be associated with changes in Bcl-2 and/or Bax activities.

Caspases, cysteine proteases with specificity to cleave after aspartic acid residues in the P1 position of substrate, are well known for the execution of apoptosis. In this study we analyzed caspase-3 and -8 activities. Among more than 13 caspases, caspase-8 is recruited to the Fas/FasL complex through the adaptor protein Fas-associated death domain and can initiate the caspase cascade (1, 11, 34). Caspase-3 is regarded as a key executioner molecule activated by apoptotic stimuli originating either at receptors for exogenous molecules or within cells through the action of drugs, toxins, or radiation (1, 11, 31, 34). The activities of caspase-3 and -8 were increased in the CPFX-treated Jurkat T cells, but only caspase-3 activity was increased in the RXM-treated Jurkat T cells.

Therefore, CPFX could induce apoptosis of activated Jurkat T cells by enhancing the expression of FasL, recruit caspase-8, and finally activate caspase-3 to execute apoptosis. By contrast, RXM increased FasL and caspase-3 activities, which were less than those of CPFX, and did not enhance the activity of caspase-8. Therefore, some differences of mechanisms inducing apoptosis of activated Jurkat T cells between CPFX and RXM could exist. These differences might be caused by biochemical and pharmacological events, such as intracellular accumulation of each drug or changes in intracellular cyclic AMP levels caused by a drug, as Aoshiba et al. noted (2), but presently this is not clear. However, it is certain that RXM could induce apoptosis of activated Jurkat T cells like CPFX, and it could be done by a different way than that of CPFX.

We used a Jurkat T-cell line in this experiment. Jurkat T cells have some differences from normal peripheral T cells. Jurkat T cells can secrete interleukin-2 when its antigen receptor is cross-linked with anti-receptor monoclonal antibodies. Also, one of the Jurkat cell line's most interesting features is that it stops growing when its antigen receptor is cross-linked (9). Although more evidence should be discovered by additional studies about immunomodulatory effects of antimicrobials on human T cells, it might be possible that CPFX or RXM induced alteration of apoptosis of a T-cell line in humans and can alter the immune response to stimuli. If these observed findings could take place in T cells in the human body, we can expect that these immunomodulatory antibiotics lessen the host tissue damage, primarily by killing the invading microorganisms and additionally by inducing apoptosis of activated T cells in infectious diseases.

In conclusion, our preliminary experiments revealed that CPFX and RXM have the potential to accelerate apoptosis of activated Jurkat T cells in vitro. This acceleration of apoptosis is conducted by inducing the expression of FasL, by interaction of more Fas and FasL, and finally by activating caspases. Further investigations about detailed and precise regulatory mechanisms in the cells, effects on the other cells (for example, normal peripheral blood cells), and clinical relevance are warranted.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Effect of CPFX (a) and RXM (b) on the viability of Jurkat T cells. Viability was measured by MTT assay from days 1 to 5 after treatment. The results are presented as means ± SEM of absorbance for triplicate measurements. OD (550 nm), optical density at 550 nm.

FIG. 2.
  • Open in new tab
  • Download powerpoint
FIG. 2.

DNA fragmentation of activated Jurkat T cells, assessed by ELISA from 12 to 72 h after CPFX or RXM treatment. The results are presented as means ± SEM of absorbance for quadruplicate measurements. Asterisks indicate a P value of <0.05 compared to that of anti-CD3 antibody-treated Jurkat T cells. OD (450 nm), optical density at 450 nm.

FOOTNOTES

    • Received 8 November 2001.
    • Returned for modification 2 September 2002.
    • Accepted 15 November 2002.
  • Copyright © 2003 American Society for Microbiology

REFERENCES

  1. 1.↵
    Andreoli, T. E. 1999. The apoptosis syndrome. Am. J. Med.107:488-506.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Aoshiba, K., A. Nagai, and K. Konno. 1995. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob. Agents Chemother.39:872-877.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, and F. Echeverri. 1995. Cell-autonomous Fas(CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature373:441-444.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Dearstyne, E. A., and N. I. Kervliet. 2002. Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced decrease in anti-CD3-activated CD4+ T cells: the role of apoptosis, Fas, and TNF. Toxicology170:139-151.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Dhein, J., H. Walczak, C. Bäumler, K. M. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1(Fas/CD95). Nature373:438-441.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Herold, C., M. Ocker, M. Ganslmayer, H. Gerauer, E. G. Hahn, and D. Schuppan. 2002. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br. J. Cancer86:443-448.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Itoh, N., Y. Tsujimoto, and S. Nagata. 1993. Effect of bcl-2 on Fas-mediated cell death. J. Immunol.151:621-627.
    OpenUrlAbstract
  8. 8.↵
    Iwai, K., T. Miyawaki, T. Takizawa, A. Konno, K. Ohta, A. Yachie, H. Seki, and N. Taniguchi. 1994. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood84:1201-1208.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Janeway, C. A., P. Travers, M. Walport, and J. D. Capra (ed.). 1999. Immunobiology, 4th ed. Elsevier Science Ltd./Garland Publishing, New York, N.Y.
  10. 10.↵
    Ju, S. T., D. J. Panka, H. Cui, R. Ettinger, M. El-Khatib, D. H. Sherr, D. H., B. Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interaction required for programmed cell death after T-cell activation. Nature373:444-448.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Juo, P., C. J. Kuno, J. Yuan, and J. Blenis. 1998. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol.8:1001-1008.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Kawasaki, S., H. Takizawa, T. Ohtoshi, N. Takeuchi, T. Kohyama, H. Nakamura, T. Kasama, K. Kobayashi, K. Nakahara, Y. Morita, and K. Yamamoto. 1998. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob. Agents Chemother.42:1499-1502.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Khan, A., T. R. Slifer, and J. S. Remington. 1998. Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob. Agents Chemother.42:1713-1717.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Koch, C. C., D. J. Esteban, A. C. Chin, M. E. Olson, R. R. Read, H. Ceri, D. W. Morck, and A. G. Buret. 2000. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. J. Antimicrob. Chemother.46:19-26.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Labro, M. T. 1997. The prohost effect of antimicrobial agents as a predictor of clinical outcome. J. Chemother.9(Suppl. 1):100-108.
    OpenUrl
  16. 16.↵
    Labro, M. T. 1998. Immunologic effects of macrolides. Curr. Opin. Infect. Dis.11:681-688.
    OpenUrlPubMed
  17. 17.↵
    Labro, M. T. 1998. Antibacterial agents-phagocytes: new concepts for old in immunomodulation. Int. J. Antimicrob. Agents10:11-21.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Labro, M. T. 2000. Interference of antibacterial agents with phagocyte functions: immunomodulation or “immuno-fairy tales”? Clin. Microbiol. Rev.13:615-650.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Liles, W. C., P. A. Kienner, J. A. Ledbetter, A. Aruffo, and S. J. Klebanoff. 1996. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med.184:429-440.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    Liu, J., C. A. Kuszynski, and B. T. Baxter. 1999. Doxycycline induced Fas/Fas ligand-mediated apoptosis in Jurkat T lymphocytes. Biochem. Biophys. Res. Commun.260:562-567.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    Morikawa, K., F. Oseko, S. Morikawa, and K. Iwamoto. 1994. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob. Agents Chemother.38:2643-2647.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Morikawa, K., H. Watabe, M. Araake, and S. Morikawa. 1996. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob. Agents Chemother.40:1366-1370.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    Murphy, K., S. B. Haudek, M. Thompson, and B. P. Giroir. 1998. Molecular biology of septic shock. New Horiz.6:181A-193A.
    OpenUrl
  24. 24.↵
    Ono, Y., Y. Ohmoto, K. Ono, Y. Sakada, and K. Murata. 2000. Effect of grepafloxacin on cytokine production in vivo. J. Antimicrob. Chemother.46:91-94.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    Purswani, M., S. Eckert, H. Arora, R. Johann-Liang, and G. J. Noel. 2000. The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down-regulation of cytokine mRNA transcription by trovafloxacin. J. Antimicrob. Chemother.46:921-929.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    Raff, M. 1998. Cell suicide for beginners. Nature396:119-122.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    Riesbeck, K., and A. Forsgren. 1994. Limited effects of temifloxacin compared with ciprofloxacin on T-lymphocyte function. Antimicrob. Agents Chemother.38:879-882.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    Sassa, K., Y. Muzushima, and M. Kobayashi. 1999. Differential modulatory effects of clarithromycin on the production of cytokines by a tumor. Antimicrob. Agents Chemother.43:2787-2789.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    Schultz, M. J., P. Speelman, S. Zaat, S. J. J. van Deventer, and T. van der Poll. 1998. Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob. Agents Chemother.42:1605-1609.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    Singh, A., and B. B. Aggarwal. 1998. Death domain receptors and their role in cell demise. J. Interferon Cytokine Res.18:439-450.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    Sun, X. M., M. MacFarlane, J. Zhuang, B. B. Wolf, D. R. Green, and G. M. Cohen. 1999. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem.274:5053-5060.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    Thompson, C. B. 1995. Apoptosis in the pathogenesis and treatment of disease. Science267:1456-1462.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    Vazifeh, D., A. Bryskier, and M. T. Labro. 2000. Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils. Antimicrob. Agents Chemother.44:511-521.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    Woodle, E. S., and H. R. Kulkarni. 1998. Programmed cell death. Transplantation65:681-691.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Effects of Ciprofloxacin and Roxithromycin on Apoptosis of Jurkat T Lymphocytes
Yong-Taek Jun, Hee-Jung Kim, Min-Jin Song, Ji-Hyang Lim, Dong-Gun Lee, Kyung-Ja Han, Su-Mi Choi, Jin-Hong Yoo, Wan-Shik Shin, Jung-Hyun Choi
Antimicrobial Agents and Chemotherapy Mar 2003, 47 (3) 1161-1164; DOI: 10.1128/AAC.47.3.1161-1164.2003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Effects of Ciprofloxacin and Roxithromycin on Apoptosis of Jurkat T Lymphocytes
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Effects of Ciprofloxacin and Roxithromycin on Apoptosis of Jurkat T Lymphocytes
Yong-Taek Jun, Hee-Jung Kim, Min-Jin Song, Ji-Hyang Lim, Dong-Gun Lee, Kyung-Ja Han, Su-Mi Choi, Jin-Hong Yoo, Wan-Shik Shin, Jung-Hyun Choi
Antimicrobial Agents and Chemotherapy Mar 2003, 47 (3) 1161-1164; DOI: 10.1128/AAC.47.3.1161-1164.2003
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
anti-infective agents
apoptosis
ciprofloxacin
Proto-Oncogene Proteins c-bcl-2
roxithromycin
T-Lymphocytes

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596